Serum Omega-6/Omega-3 Ratio and Risk Markers for Cardiovascular Disease in an Industrial Population of Delhi

Ruby Gupta¹,², Ramakrishnan Lakshmy³, Ransi Ann Abraham³, Kolli Srinath Reddy⁴, Panniyammakal Jeemon², and Dorairaj Prabhakaran²,⁴
¹South Asia Network for Chronic Disease, New Delhi, India
²Center for Chronic Disease Control, New Delhi, India
³Department of Cardiac Biochemistry, AIIMS, New Delhi, India
⁴Public Health Foundation of India, New Delhi, India

Abstract

High omega-6/omega-3 ratio intake promotes development of many chronic diseases. Secondary prevention studies though have demonstrated a decline in progression of many such diseases after reducing the intake, specific biochemical indices of cardiovascular disease risk markers have not been evaluated. We have evaluated the circulating levels of omega-6/omega-3 ratio and its effect on cardiovascular risk markers in India. Present study was conducted in industrial setting where employees were randomly selected. Data on their demographic characteristics were collected using pre-tested questionnaire. Fasting blood samples were collected from all the participants. Serum was separated and stored at −80°C till the time of analysis. Lipids were estimated using standard kits. Fatty acids in serum were estimated by Gas chromatography. The identified Omega-3 fatty acid included were 18:3 (Alpha-linolenic acid), 20:5 (Eicosapentenoic acid) & 22:6 (Docosahexenoic acid). Among omega-6 included were 18:2 (linoleic acid), 18:3 (gamma-linolenic acid) & 20:4 (Arachidonic acid). Complete data was available for 176 participants (89% males and 11% females) with mean age of 47.23 ± 6.00 years. The bmi of the participants was 24.88 ± 3.43 Kg/m² and waist circumference was 91.50 ± 9.56 cm. The median of omega-6/omega-3 ratio in the study population was 36.69 (range: 6.21 - 183.69). The levels of total cholesterol, triglycerides, ldl-cholesterol and cholesterol/hdl ratio and apo B correlated significantly with omega-6/3 ratio. There was no correlation observed with hsCRP and LDL-particle size. A direct relationship of omega-6/omega-3 ratio with dyslipidemia was observed in our study.

Keywords
Omega Fatty Acids; Dyslipidemia; Omega 6/3 Ratio; CHD; hs CRP

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (http://creativecommons.org/licenses/by/4.0/)
ruby.gupta@phfi.org.
1 Introduction

A balance between omega-6/omega-3 of 1/1 existed in the food of all the wild animals and human beings for millions of years. Since last 10,000 years with the growth of agriculture there is a rapid change in food habits of human being and a drastic change observed in the last 150 years with rapid industrialization and urbanization [1]. It has resulted in increased uptake of high energy food and lesser expenditure of energy (low physical activity), high intake of omega-6 fatty acids (from cereals and grains) and less intake of omega-3 fatty acid resulting in high omega-6/omega-3 ratio. Intake as high as 15 has been reported from UK & north Europe and 16 - 74 from US as compared to 1 - 2 from Greece (before year 1960) and 4 from Japan. However, the WHO recommendation of omega-6/omega-3 ratio is 5 - 8 which should form 1% - 2% of total energy intake per day [2].

A very high omega-6/omega-3 ratio promotes pathogenesis of many chronic diseases like cardiovascular disease, cancer, inflammatory and autoimmune disease, rheumatoid arthritis, asthma, whereas increased intake of omega-3 fatty acids (reduced omega-6/omega-3 ratio) suppresses the effect [3]. Secondary prevention studies have demonstrated a decline in disease progression or reversal of symptoms with decline in ratio; however the optimal level varies with the disease under consideration [4].

Relatively high intake of omega-6/omega-3 ratio of 38 - 50 and 5 - 6.1 has been reported from urban and rural India respectively [5,6]. There has always been emphasis to maintain a lower ratio of omega-6/omega-3 in the dietary intake on the basis of studies evaluating the effects of dietary n-3 PUFA on biochemical indices of CHD risk [7] and an improvement in Insulin resistance [8,9]. With the advancement of time, there is an increase in urbanization and a rapid change in food habits, there is also an accumulation of risk markers resulting in multifactorial diseases like CVD to manifest earlier in life. We did not find any study which has evaluated the circulating levels of omega-6/omega-3 ratio and affected cardiovascular risk markers in India.

2 Material & Methods

The present study was conducted in industrial setting where employees were randomly selected. Individuals with known history of diabetes, heart disease, stroke, chronic renal failure, thyroid abnormalities or cancer were not included for the study. Also individuals who reported having taken during the previous 3 months dietary supplements or medications known to alter lipid or glucose metabolism (for example, plant sterol-enriched foods or supplements, fish oil supplements, lipid-lowering drugs, steroids, β-blockers, insulin or oral hypoglycaemic drugs) were excluded from the study. Informed consent was taken from all the participants. Ethical clearance for the present study was obtained from the institutes.

Data on their demographic characteristics were collected using pre-tested questionnaire. Fasting blood samples were collected from all the participants in plain tube using vacutainers from BD. Serum was separated and stored at −80°C till the time of analysis.

Cholesterol, triglycerides, HDL-c, LDL-c, Apo-A1, Apo-B was estimated using kits from Sentinel Diagnostic (Milan, Italy) on CX9 autoanalyzer from Beckman Coulter. hsCRP was
estimated by latex enhanced immune-turbidimetry. LDL-particle size was estimated using polyacrylamide slab gel electrophoresis [10]. Fatty acids were estimated in serum by Gas chromatography as a marker of dietary fatty acid intake in the last few days using method of Leepage & Roy, 1986 [11]. Total 31 fatty acids were identified using standards from Supelco. Fatty acids are expressed as percentage of total fatty acids identified. The identified omega-3 fatty acid included were 18:3 (Alpha-linolenic acid), 20:5 (Eicosapentenoic acid, epa) & 22:6 (Docosahexenoic acid, dha). Among omega-6 included were 18:2 (linoleic acid), 18:3 (gamma-linolenic acid) & 20:4 (Arachidonic acid).

Statistical analysis was carried using STATA 9.0 (College station, Texas, USA). The strength of relationship between lipid profile and fatty acids ratio were calculated using pearson/spearman rank correlation whichever was appropriate for the distribution of the data. p value less than 0.05 were considered statistically significant.

3 Results

Complete data was available for 176 participants (89% males and 11% females) with mean age of 47.23 ± 6.00 years. The mean body mass index (BMI) of the participants was 24.88 ± 3.43 Kg/m² and mean waist circumference was 91.50 ± 9.56 cm (Table 1). The median of omega-6/omega-3 ratio in the study population was 36.69 (range: 6.21 - 183.69) (Table 2). High levels of omega-6/3 ratio associated with increased total cholesterol, triglycerides, LDL-cholesterol, cholesterol/hdl-c ratio and apo B levels (Table 3). There was no correlation observed with hsCRP, LDL- particle size, abdominal obesity and body mass index. On regression analysis, omega-6/omega-3 ratio was significantly associated with cholesterol/hdl-c ratio and remained significant even after adjustment with non modifiable risk markers.

Omega-3 fatty acids when analyzed separately were associated with low levels of total cholesterol and cholesterol/hdl ratio. Individually, high levels of alpha-linoleic acid (ALA) correlated with lower BMI and higher levels of epa + dha correlated significantly with lower levels of cholesterol, triglycerides, cholesterol/hdl-c ratio and apo B levels. The relationship of ALA with BMI and epa + dha with chol/HDL ratio was significant on regression analysis and remained significant even after adjustment with age and sex.

Among omega-6 fatty acids, Linoleic acid (18:2) was inversely associated with triglyceride levels (r = −0.38, p = 0.02). The hypotriglyceridemic effect of linoleic acid was found significant on regression and remained significant after adjustment with other non-modifiable risk factors.

4 Discussion

Linoleic acid (18:2) of the omega-6 and linolenic acid (18:3) of omega-3 family are known as essential fatty acids (EFA) because human beings cannot synthesize these fatty acids and must obtain them from diet. These fatty acids in the human body undergo elongation and desaturation procedure to produce very-long chain fatty acids. There is competition between omega-6 and omega-3 fatty acids for the desaturation enzyme. However, both D-4 and D-6 desaturases prefer omega-3 to omega-6 fatty acids [12,13]. A high LA intake interferes with
the desaturation and elongation of ALA [14,15]. Mammalian cells cannot convert omega-6 to omega-3 fatty acids because they lack the converting enzyme, omega-3 desaturase.

The direct relationship of omega-6/omega-3 ratio with dyslipidemia observed in our study was not found else-where in literature except for one wherein subjects were given a combination omega-3 PUFA from fish oil and plant sterols resulted in reduction in cholesterol/hdl-c ratio [16]. High prevalence (40.2 % in men & 34.4% in women) [17] and early appearance (between the age 31 - 40 years) of dyslipidemia (cholesterol/hdl-c ratio ≥ 4.5) puts Indians at risk of developing coronary artery disease early in life [18]. A balance in omega-6/omega-3 intake has always been advocated for optimal health. Apart from increase in omega-3 intake by the vegetarians in the form of supplement, there is a need of reduction in absolute omega-6 fatty acid intake.

We did not find any association with omega-6/omega-3 ratio with hs CRP. Dietary supplementation of low fat high complex carbohydrate diet supplemented with omega-3 fatty acid for 12-weeks did not result in any significant change in CRP in LIPGENE study [19].

A review of placebo-controlled, crossover or parallel design studies by Harris WS, 1997 [20] revealed that both omega-6 and ALA (omega-3) polyunsaturated fatty acids are equivalent in their effect on lipid & lipoproteins. Kinetics studies have shown that omega-3 fatty acids exert their hypocholesterolemic effect through lowering of apo B synthesis thereby reducing conversion of VLDL to LDL [21]. However, omega-6 fatty acids on the other hand exert hypolipidemic effects through increasing LDL catabolism. We observed a cholesterol lowering effect of omega-3 fatty acid which also has an impact on the chol/hdl-c ratio.

The preventive effect of epa & dha has been identified by studies since seventies in Greenland Eskimos [22], through Seven country study [23]. The significant inverse association of epa + dha with triglyceride levels in our study possibly contributes through increased clearance of chylomicron triglyceride by increasing LPL activity [24].

The major limitation of the study was that information on dietary intake was not available which would have been extremely useful in the strengthening the correlations especially percent fat and carbohydrate intake which are direct determinants of circulating triglyceride levels.

5 Conclusion

There is a highly skewed omega-6/omega-3 ratio intake in the study population and its strong association with dyslipidemia suggests disturbances in lipid metabolism, which need to be further evaluated.

References

[1]. Simopoulos AP. The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases. Experimental Biology and Medicine. 2008; 233(6):674–688. DOI: 10.3181/0711-MR-311 [PubMed: 18408140]
[2]. WHO Technical Report Series 916. Diet, Nutrition & the Prevention of Chronic Diseases. WHO; Geneva: 2003.

[3]. Simopoulos, AP., Cleland, LG. Omega-6/Omega-3 Essential Fatty Acid Ratio: The Scientific Evidence. Karger; Basel: 2003.

[4]. Simopoulos AP. The Importance of the Ratio of Omega-6/Omega-3 Essential Fatty Acids. Biomed Pharmacother. 2002; 56(8):365–379. DOI: 10.1016/S0753-3322(02)00253-6 [PubMed: 12442909]

[5]. UdiPI SA, Karandikar SA, Mukherjee R, Agarwal S, Ghurge PS. Variations in Fats and Fatty Acid Intake in Adult Males of Three Regions of India. Indian Journal of Public Health. 2006; 50(3): 179–186. [PubMed: 17191405]

[6]. Pella, D., Dabnav, G., Singh, RB., Sharma, R. Effects of an Indo-Mediterranean Diet on Omega-6/Omega-3 Ratio in Patients at Risk of CAD: The Indian Paradox. Karger; Basel: 2003.

[7]. Ghafoorunissa, Vani, Laxmi R, Sesikeran B. Effects of Dietary Alpha-Linolenic Acid from Blended Oils on Biochemical Indices of Coronary Heart Disease in Indians. Lipids. 2002; 37(11):1077–1086. DOI: 10.1007/s11745-002-1003-2 [PubMed: 12558058]

[8]. Raheja BS, Sadikot SM, Pathak RB, Rao MB. Significance of n-6/n-3 Ratio for Insulin Action in Diabetes. Annals New York Academy of Sciences. 1993; 683:258–271.

[9]. Ghafoorunissa, Ibrahim A, Natarajan S. Substituting Dietary Linoleic Acid with Alpha-Linolenic Acid Improves Insulin Sensitivity in Sucrose Fed Rats. Biochim Biophys Acta. 2005; 1733(1): 67–75. DOI: 10.1016/j.bbadis.2004.12.003 [PubMed: 15801047]

[10]. Singh Y, Lakshmy R, Gupta R, Kranthi V. A Rapid 3% POLYACRYLAMIDE SLAB GEL ELECTROPHORESIS Method for High Throughput Screening for LDL Phenotype. Lipids in Health & Diseases. 2008; 7:47–52. DOI: 10.1186/1476-511X-7-47

[11]. Lepage G, Roy CC. Direct Transesterification of All Classes of Lipids in a One-Step Reaction. Journal of Lipid Research. 1986; 27:114–120. [PubMed: 3958609]

[12]. Hague TA, Christoffersen BO. Evidence for Peroxisomal Retroconversion of Adrenic Acid (22:4n6) and Docosahexaenoic Acid (22:6n3) in Isolated Liver Cells. Biochim Biophys Acta. 1986; 875(2):165–173. DOI: 10.1016/0005-2760(86)90165-7 [PubMed: 2935195]

[13]. Hague TA, Christoffersen BO. Effect of Dietary Fats on Arachidonic Acid and Eicosapentaenoic Acid Biosynthesis and Conversion to C22 Fatty Acids in Isolated Liver Cells. Biochim Biophys Acta. 1984; 796(2):205–217. DOI: 10.1016/0005-2760(84)90349-7 [PubMed: 6093889]

[14]. Emken, EA., Adlof, RO., Rakoff, H., Rohwedder, WK. Metabolism of Deuterium-Labeled Linoleic, Linoleic, Oleic, Stearic and Palmitic Acid in Human Subjects. Synthesis and Application of Isotopically Labeled Compounds. Baillie, TA., Jones, JR., editors. Vol. 1989. Elsevier Science Publishers; Amsterdam: 1988. p. 713-716.

[15]. Indu M, Ghafoorunissa. n-3 Fatty Acids in Indian Diets—Comparison of the Effects of Precursor (Alpha-Linolenic Acid) versus Product (Long Chain n-3 Polyunsaturated Fatty Acids). Nutrition Research. 1992; 12(4–5):569–582. DOI: 10.1016/S0271-5317(05)80027-2

[16]. Khandelwal S, Demonty I, Jeemon P, Lakshmy R, Mukherjee R, Gupta R, Snehj U, Niveditha D, Singh Y, van der Knaap HCM, Passi SJ, et al. Independent and Interactive Effects of Plant Sterols and Fish Oil n-3 Long-Chain Polyunsaturated Fatty Acids on the Plasma Lipid Profile of Mildly Hyperlipidaemic Indian Adults. British Journal of Nutrition. 2009; 102(5):722–732. DOI: 10.1017/S0007114509297170 [PubMed: 19296875]

[17]. Reddy KS, Prabhakaran D, Chaturvedi V, Jeemon P, Thankappan KR, Ramakrishnan L, Mohan BVM, Pandav CS, Ahmed FU, Joshi PP, Meera R, et al. Methods for Establishing a Surveillance System for Cardiovascular Diseases in Indian Industrial Population. Bull World Health Organ. 2006; 84(6):461–469. DOI: 10.2471/BLT.05.027037 [PubMed: 16799730]

[18]. Sawant AM, Shetty D, Manekshwar R, Ashavaid TF. Prevalence of Dyslipidemia in Young Adult Indian Population. JAPI. 2008; 56:99–102. [PubMed: 18472509]

[19]. Petersson H, Risérus U, McMonagle J, Gulseth HL, Tierney AC, Morange S, HelaL O, Shaw DI, Ruano JA, López-Miranda J, Kiec-Wilk B, et al. Effects of Dietary Fat Modification on Oxidative Stress and Inflammatory Markers in the LIPGENE Study. British Journal of Nutrition. 2010; 104(9):1357–1362. DOI: 10.1017/S000711451000228X [PubMed: 20569506]
[20]. Harris WS. n-3 Fatty Acids & Serum Lipoproteins: Human Studies. The American Journal of Clinical Nutrition. 1997; 65(Suppl. 5):1645S–1654S. [PubMed: 9129504]

[21]. Illingworth DR, Harris WS, Connor WE. Inhibition of Low Density Lipoprotein Synthesis by Dietary Omega-3 Fatty Acids in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology. 1984; 4:270–275. DOI: 10.1161/01.ATV.4.3.270

[22]. Parkinson AJ, Cruz AL, Heyward WL, Bulkow LR, Hall D, Barstaed L, Connor WE. Elevated Concentrations of Plasma ω-3 Polyunsaturated Fatty Acids among Alaskan Eskimos. The American Journal of Clinical Nutrition. 1994; 59:384–388. [PubMed: 8310989]

[23]. Hu FB, Bronner L, Willet WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE. Fish & Omega-3 Fatty Acid Intake and Risk of CHD in Women. JAMA. 2002; 287(14):1815–1821. DOI: 10.1001/jama.287.14.1815 [PubMed: 11939867]

[24]. Park Y, Harris WS. Omega-3 Fatty Acid Supplementation Accelerates Chylomicron Triglyceride Clearance. Journal of Lipid Research. 2003; 44:455–463. DOI: 10.1194/jlr.M200282-JLR200 [PubMed: 12562865]
Table 1
Baseline characteristics of the study population.

|                          | Value                  |
|--------------------------|------------------------|
| Numbers                  | 176                    |
| Mean age (years)         | 47.23 ± 6.00           |
| Sex (%)                  | 89% Males              |
| Mean waist circumference (cm) | 91.5 ± 9.56         |
| Mean BMI (Kg/m^2)        | 24.88 ± 3.43           |
| Smokers (%)              | 38 (21.6%)             |
| Alcohol intake (%)       | 62 (35%)               |
| Mean Systolic Blood Pressure (mmHg) | 127.39 ± 15.65 |
| Mean Diastolic Blood Pressure (mmHg) | 81.10 ± 10.46 |
Table 2
Biochemical Profile & fatty acid levels of the study participants.

| Parameters                        | Mean SD/Median (range) |
|-----------------------------------|------------------------|
| Cholesterol (mg/dl)               | 194.66 ± 30.70<sup>a</sup> |
| Triglycerides (mg/dl)             | 139.52 ± 62.35<sup>a</sup> |
| HDL-c (mg/dl)                     | 37.47 ± 9.31<sup>a</sup>  |
| LDL-c (mg/dl)                     | 130.76 ± 28.69<sup>a</sup> |
| Cholesterol/HDL ratio             | 5.37 ± 1.00<sup>a</sup>  |
| Apolipoprotein A<sub>1</sub> (mg/dl)| 125.77 ± 23.72<sup>a</sup> |
| Apolipoprotein B (mg/dl)          | 106.93 ± 20.01<sup>a</sup> |
| Hs CRP (mg/l)                     | 1.7 (0.01 - 100)<sup>b</sup> |
| LDL-particle size (nm)            | 26.96 ± 0.49<sup>a</sup>  |
| Alpha-linolenic acid (ω-3)        | 0.085 (0.01 - 2.43)<sup>b</sup> |
| Eicosapentenoic acid (ω-3)        | 0.49 (0.05 - 2.44)<sup>b</sup> |
| Docosahexenoic acid (ω-3)         | 0.54 (0.02 - 2.76)<sup>b</sup> |
| Linoleic acid (ω-6)               | 31.80 ± 5.05<sup>a</sup>  |
| Gamma-linolenic acid (ω-6)        | 0.036 (0.01 - 1.89)<sup>b</sup> |
| Arachidonic acid (ω-6)            | 5.42 ± 1.72<sup>a</sup>  |
| Omega-6/Omega-3 ratio             | 36.69 (6.21 - 183.69)<sup>b</sup> |

<sup>a</sup>Values are expressed as Mean ± SD;
<sup>b</sup>Values are expressed as Median (range).
Table 3
Correlation of omega-6/omega-3 ratio with bio-chemical risk markers.

| Risk markers          | Correlation coefficient | p value |
|-----------------------|-------------------------|---------|
| Cholesterol           | 0.203                   | 0.02\(^c\) |
| Triglycerides         | 0.187                   | 0.04\(^c\) |
| HDL-c                 | -0.071                  | 0.44    |
| LDL-c                 | 0.189                   | 0.03\(^c\) |
| Cholesterol/HDL-c ratio | 0.27                  | 0.002\(^c\) |
| Apo A1                | -0.037                  | 0.42    |
| Apo B                 | 0.204                   | 0.02\(^c\) |
| LDL-size              | -0.04                   | 0.66    |
| hsCRP                 | -0.077                  | 0.40    |

\(^c\)Values are significant, p < 0.05.